Florence Healthcare has entered a collaboration with Pfizer to support a global Phase 2/3 COVID-19 vaccine study leveraging its site and sponsor connectivity platform across 27 countries, with more than 7,200 research sites and 18,000 research professionals. This extensive network of connectivity will support the COVID-19 trial in a digital capacity, as onsite visits and collaboration are restricted due to the pandemic. With support from Florence’s Remote Site Monitoring Module, coupled with...